{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009162","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.199369+00:00","generated_at":"2026-06-17T21:42:41.371295+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rani Therapeutics reports FY2022 net loss $63.3M; cash $98.5M; RT-102 Phase 2 in H2 2023","bullets":["Net loss $63.3M for 2022, vs $53.1M in 2021; cash $98.5M, sufficient to mid-2024.","Phase 1 data for RT-102 (osteoporosis) positive; FDA agrees 505(b)(2) pathway; Phase 2 planned H2 2023.","Partnership with Celltrion for RT-111 (ustekinumab biosimilar); exclusive license with right of first negotiation.","Expects to start three Phase 1 studies in 2023 for RT-105, RT-110, RT-111."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009162","json":"https://secwatch.observer/filing/0000950170-23-009162.json","markdown":"https://secwatch.observer/filing/0000950170-23-009162.md","text":"https://secwatch.observer/filing/0000950170-23-009162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023009162/0000950170-23-009162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023009162/rani-20230322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:42:41.371295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"013755e0ae10ec8f76b85b87035a72299ed0ffc5","claim":"Rani Therapeutics Holdings, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income Net loss for the three and twelve months ended December 31, 2022 was $17.3 million and $63.3 million, respectively.","evidence_excerpt":"On March 22, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023009162/0000950170-23-009162-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the three and twelve months ended December 31, 2022 was $17.3 million and $63.3 million, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}